阿卡拉布鲁丁尼通过调节胆酸代谢来缓解与代谢功能障碍相关的脂肪性肝病
Yanbo Wang1, Shiwei Chen1, Bingjue Ye1
1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
The international journal of biochemistry & cell biology
|April 30, 2025
概括
阿克拉布鲁丁尼,一个布鲁顿.
科学领域:
- 肝病学和代谢疾病
- 药理学和药物发现
- 免疫学和炎症 免疫学和炎症
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 是一个日益严重的全球健康问题,治疗选择有限.
- 布鲁顿的氨酸激酶 (BTK) 信号与MASLD的进展有关,这表明BTK抑制剂是潜在的治疗方法.
- 已知BTK抑制剂阿克拉布鲁替尼之前没有研究其对MASLD的影响.
研究的目的:
- 在MASLD的小鼠模型中研究aclabrutinib的治疗疗效.
- 阐明阿克拉布鲁替尼可能缓解MASLD的潜在机制.
- 探索针对BTK用于MASLD治疗的潜力.
主要方法:
- 一个高脂肪饮食诱导的小鼠模型被用来复制MASLD.
- 用aclabrutinib治疗小鼠,以评估其对肝脏病理和代谢参数的影响.
- 进行了基因表达分析,代谢分析和肠道微生物群评估.
主要成果:
- 在小鼠中,Aclabrutinib治疗显著改善了与MASLD相关的病理特征.
- 阿克拉布鲁丁尼增强了能量消耗,促进了热生成和脂解,并抑制了脂质吸收.
- 治疗调节了胆酸代谢,恢复了肠道微生物群的平衡,并改变了相关受体表达.
结论:
- 阿克拉布鲁丁尼通过向BTK,证明了对MASLD的显著治疗潜力.
- 药物的有效性与其调节胆酸代谢,肠道微生物群,热生成和脂解的能力有关.
- 这些发现支持进一步研究阿克拉布鲁替尼和其他BTK抑制剂作为MASLD的新治疗方法.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
478
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
478
01:17Hepatic Drug Excretion: Enterohepatic Cycling
874
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
874
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
21
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
21
01:17Chronic Bowel Disorders: Introduction
363
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
363
01:29Chronic Pancreatitis II: Collaborative Care
50
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
50
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
111
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
111